antagomir

An antagomiR, also written as antagomir, is a chemically engineered antisense oligonucleotide designed to inactivate endogenous microRNAs (miRNAs) in vivo. By binding to a mature miRNA, an antagomiR prevents the miRNA from associating with its target mRNAs, thereby derepressing the miRNA’s gene targets and altering downstream pathways. The approach is used primarily as a research tool to study miRNA function and as a basis for therapeutic strategies.

Most antagomiRs are 20–22 nucleotides in length and are complementary to the mature miRNA sequence. They are commonly modified with chemical groups such as 2'-O-methyl or 2'-O-methoxyethyl (2'-MOE) to enhance affinity and stability, and they often carry a phosphorothioate backbone for nuclease resistance. A cholesterol or other lipid conjugate is frequently added to improve cellular uptake and biodistribution after systemic administration, facilitating delivery to liver and other tissues.

Mechanistically, antagomiRs bind to their target miRNA and either sequester it away from the RNA-induced silencing complex (RISC) or prevent miRNA-mRNA interactions, reducing miRNA activity. The chemical modifications and conjugates influence tissue distribution, pharmacokinetics, and duration of silencing.

Applications and status: antagomiRs are widely used in preclinical models to elucidate miRNA function and disease mechanisms, with demonstrations of phenotype changes upon miRNA silencing. Therapeutic development has explored antagomiRs for metabolic, cardiovascular, and oncologic indications, but challenges remain in achieving precise tissue delivery, minimizing off-target effects, and managing potential immune responses.